- Germantown, MD
- Xceleron provides accelerator mass spectrometry technology to deliver bio-based solutions for drug development activities.
Xceleron Ltd entered administration (chapter 11) on January 10th 2012 with debts of £7m. It provided bioanalytical accelerator mass spectrometry (AMS) services for drug development. It conducted microdosing, pre-clinical evaluation, intravenous pharmacokinetics, metabolite profiling, and mass balance investigations in humans. The company served the pharmaceutical and biotechnology markets. Xceleron Ltd was formerly known as The Centre for Biomedical Accelerator Mass Spectrometry Ltd. and changed its name to Xceleron Ltd in 2003. The company was founded in 1997 and was headquartered in York, the United Kingdom with a facility in Maryland.
Current Team (4)Update
Funding Rounds (3) - $6.1MUpdate
Board Members and Advisors (2)Update
Our investment management team has created market leading investment performance for the...
Solon is a venture capital firm based in the UK that invests in the healthcare and technology...
Frog invests in Europe’s most ambitious growth stage companies
Albion Investors (â€œAlbionâ€) is a private investment firm based in New York, NY. Since 1995...
Venture capital investors
venture capital firm
20340 Seneca Meadows Parkway
Germantown, MD 20876